Consistency of PD-L1 Detecting Method Between E1L3N and 22C3 Monoclonal Antibodies in NSCLC Patients
NCT05129462 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 52
Last updated 2021-12-03
Summary
Evaluated the correlation between the qualitative test results of Xiamen Aide PD-L1 antibody reagent (immunohistochemistry) and the efficacy of Keytruda single-agent therapy, and the research data is used to support the registration and marketing of the assessment reagent
Conditions
- Non Small Cell Lung Cancer
Sponsors & Collaborators
-
Hunan Province Tumor Hospital
lead OTHER
Principal Investigators
-
Yongchang Zhang, MD · Hunan Cancer Hospital
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2018-08-05
- Primary Completion
- 2021-09-05
- Completion
- 2021-10-01
Countries
- China
Study Locations
More Related Trials
-
68Ga-grazytracer PET/CT for Early Assessment of Response to Neoadjuvant Immunotherapy in Resectable NSCLC
NCT06756217 ·Status: RECRUITING
-
irAE Prediction of Anti-PD-1/L1 in Lung Cancer
NCT05288569 ·Status: UNKNOWN
-
Deep Learning Signature for Predicting Occult Nodal Metastasis of Clinical N0 Lung Cancer
NCT05425134 ·Status: UNKNOWN
-
Precision Diagnosis for Intraoperative Frozen Section of Early Stage Lung Cancer
NCT02941003 ·Status: UNKNOWN ·Phase: NA
-
PD-L1 PET Imaging in Patients With the Immunotherapy for Non-small Cell Lung Cancer
NCT05533086 ·Status: UNKNOWN
-
Clinical Research for the Consistency Analysis of PD-L1 in Cancer Tissue and Plasma Exosome
NCT02890849 ·Status: COMPLETED ·Phase: NA
-
PD-L1 Expression in Lung Cancer
NCT04992715 ·Status: UNKNOWN ·Phase: PHASE2
-
Molecular Subtyping of Extensive Stage Small Cell Lung Cancer and Relevent Clinical Significance
NCT05933863 ·Status: COMPLETED
-
A Study of Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLC
NCT06443684 ·Status: RECRUITING
-
A Clinical Study on the Analysis of Risk Factors for the Occurrence of PD-1/PD-L1 Inhibitor-associated Liver Injury in Lung Cancer Patients
NCT06402981 ·Status: RECRUITING
-
68Ga-NK224 PET Imaging of PD-L1 Expression in Cancers
NCT06754345 ·Status: RECRUITING
-
Chromosomal Instability as a Surrogate Biomarker of Drug Resistance in Immunotherapy for Lung Cancer Patients
NCT04203095 ·Status: UNKNOWN
-
Study of Longitudinal Plasma PD-L1 Testing With Immunotherapy in Lung Cancer
NCT06849518 ·Status: RECRUITING ·Phase: NA
-
The Predictive Biomarkers in Patients With Locally Advanced Non-small Cell Lung Cancer
NCT06287320 ·Status: RECRUITING
-
Monitoring the Changes of Tumor-related Biomarkers Before and After Pulmonary Nodule Biopsy.
NCT03397355 ·Status: UNKNOWN
-
99mTc-H7ND SPECT/CT Imaging in NSCLC
NCT05999214 ·Status: RECRUITING ·Phase: NA
-
Immune Signature Analysis of Disease Progression in Post Immunotherapy Lung Cancer Patients
NCT05415358 ·Status: ACTIVE_NOT_RECRUITING
-
Retrospective Observational Study on Prediction of Response to PD-1 Immunotherapy in Patients with NSCLC
NCT04886401 ·Status: RECRUITING
-
Deep Learning Signature for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma
NCT05736991 ·Status: UNKNOWN
-
Low-dose Protocol for Computed Tomography-guided Lung Biopsy
NCT02971176 ·Status: COMPLETED ·Phase: NA
-
Foundation and Clinical About the Expression of PD-1 in Peripheral Blood T Lymphocytes
NCT05792995 ·Status: COMPLETED ·Phase: PHASE2
-
Prospective Observation of Failure Patterns in NSCLC Treated With ICIs
NCT04492969 ·Status: UNKNOWN
-
The Predictive Role of Programmed Death Ligand 1 (PD-L1) and Neutrophil to Lymphocyte Ratio (NLR) in Non-Small Cell Lung Cancer (NSCLC)
NCT03816657 ·Status: UNKNOWN
-
Risk Stratification of Patients Using the Lung Cancer Biomarker Panel in China
NCT01928836 ·Status: COMPLETED
-
Evaluation of Clinical Significance and Feasibility of CT Guided Biopsy of Double Site Lesions：A Preliminary Lung Centered Study
NCT04960631 ·Status: COMPLETED